Jim Meyers

Jim brings more than 30 years of worldwide commercial leadership experience within the biotechnology industry. He currently serves on the Board of Directors of three public biotech companies – Sangamo Therapeutics, Arbutus Biopharma, and CytomX Therapeutics – and as a Senior Advisor to the Boston Consulting Group (BCG), Biogen, and the Biotechnology Innovation Organization (BIO). Jim has also served as a senior advisor to Gilead Sciences since his retirement from Gilead in February 2018. Prior to his advisory role, Jim most recently served as Gilead’s executive vice president of worldwide commercial operations where he was responsible for all commercial activities, including pricing and market access in North America, Europe, Middle East, Australia, and Japan. Over his 22-year career at Gilead, Jim led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutic areas of HCV and HIV. Prior to joining Gilead, Jim held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA.

Jim holds a B.S. in economics from Boston College.